Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388674 | 1.00 | CYP2C19 (0.51) | CYP2C19ALDH1A1KDM4EPOLBPKM | |
| SCHEMBL6427337 | 0.81 | ALDH1A1 (0.50) | CYP2C19ALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL6430684 | 0.81 | ALDH1A1 (0.50) | CYP2C19ALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL6506436 | 0.80 | TSHR (0.53) | ALDH1A1KDM4EPOLBPKMMEN1 | |
| SCHEMBL6500660 | 0.80 | TSHR (0.53) | ALDH1A1KDM4EPOLBPKMMEN1 | |
| SCHEMBL6502545 | 0.80 | TSHR (0.53) | ALDH1A1KDM4EPOLBPKMMEN1 | |
| SCHEMBL6428309 | 0.80 | GRM7 (0.46) | CYP2C19ALDH1A1KDM4EPOLBPKM | |
| SCHEMBL1605788 | 0.79 | TSHR (0.46) | ALDH1A1KDM4EPOLBPKMSMN1; SMN2 | |
| SCHEMBL6501483 | 0.77 | TSHR (0.55) | CYP2C19ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL6426299 | 0.77 | GRM7 (0.46) | ALDH1A1POLBKMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | CYP2C19 89/4885ALDH1A1 67/4885KDM4E 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.